K20 and ICO-10 monoclonal antibodies (gp120/200; Thy-1): immunophenotyping of human solid tumours. by Kadagidze, Z. G. et al.
Br. J. Cancer (1990), 61, 215 217
K20 and ICO-10 monoclonal antibodies (gpl20/200; Thy-1):
immunophenotyping of human solid tumours
Z.G. Kadagidze', N.N. Tupitsyn', A.J. Baryshnikov', Kh.P. Kadyrov', V.M. Blinov2,
A. Bernard3, M. Amiot4 & L. Boumsell4
'Laboratory ofClinical Radioimmunology and 2Department ofPathoanatomy ofHuman Tumours, All-Union Cancer Research
Centre ofthe AMS USSR, Kashirskoye shosse 24, Moscow 115478, USSR; 3Laboratoire d'Immunologie des Tumeurs de l'Enfant,
Institut Gustave Roussy, Villejuif, France; and 4INSERM U93, Universite de Paris VII, Institut de Recherches sur les Maladies du
Sang, H6pital Saint-Louis, Paris, France.
Summary Solid tumour cells were shown to express VLA-P and Thy-I antigens. For identification of these
molecules two monoclonal antibodies, K-20 and ICO-10, characterised in detail previously, were used. Four
groups of solid tumours have been identified according to their immunophenotype: VLA-P+ and Thy-I ;
VLA-P' and Thy-I+; VLA-p- and Thy-I+; VLA-p- and Thy-l. To a certain extent these groups have been
shown to reflect tumour histogenesis: tumours of epithelial origin never expressed an ICO-10+, K20-
phenotype while soft tissue sarcomas and neuroblastoma cells never expressed the P-chain of VLA molecular
complexes.
Human Thy-I antigen has a unique pattern of expression on
haemopoietic cells: it has been found on a minority of thy-
mocytes and late pre-B/early B cells (Ritter et al., 1983). In
immunodiagnosis of haemoblastoses this antigen is helpful as
an additional marker for differentiation of malignant lym-
phoblasts (Tupitsyn et al., 1987; Peterson et al., 1986). Thy-I
antigen expression on cerebral tissue is one of its characteris-
tic features as shown previously (Casper et al., 1977; Danon
et al., 1980; McKenzie & Farbe, 1981). With the use of
anti-Thy-I monoclonal antibody (Mab) 390, Seeger et al.
(1982) also found this antigen on fibroblasts and the majority
of neuroblastomas. Recent investigations have demonstrated
a more variable pattern of tissue distribution of normal and
malignant cells expressing Thy-I antigen coded by the gene
located in chromosome 1. This antigen has also been found
on a number of small round cell tumours. Thus, Kl and
MC 139 Mabs reacted with neurogen cells, fibroblasts, with
most sarcomas, choriocarcinomas, teratocarcinomas and en-
dothelial and unstriated muscle cells, while no reaction with
normal and malignant epithelial cells was noted (Retting et
al., 1985). ICO-10 Mabs against Thy-I antigen also reacted
with neuroblastoma cells in most cases and with some T- and
B-cell leukaemias and lymphosarcomas (Zikiryakhodzhaev et
al., 1987; Baryshnikov et al., 1985a).
K20 (CD 29) Mab recognising VLA molecular complexes
are also helpful for immunophenotyping of tumours and
haemoblastoses. Their pattern of tissue distribution is quite
different (Amiot et al., 1986). ICO-10 and K20 Mabs were
shown to have different patterns of reactivity with some
tumour cells, subpopulations of B- and T-cells (Baryshnikov,
1984; Amiot et al., 1986). The choice of these two mono-
clonals was based on the results of pre-screening studies
involving various solid tumours and 17 antibodies from the
well established clasters of differentiation (CD 1,2,5,7,8,10,
11,15). The present study aimed to assess the value of com-
bined application of two types of Mabs reacting with solid
tumour cells in terms of clinical immunodiagnosis.
Materials and methods
Clinical data
Tumour tissue samples were obtained from 66 patients dur-
ing surgical removal of their tumours: varying types of neuro-
blastoma (24 cases), neurosarcoma (2), malignant neurolem-
moma (2), nephroblastoma (13), various types of soft tissue
sarcomas (10), immature teratoma (2), hepatoblastoma (2),
adrenal cortex adenoma (2), squamous cell cancer of the
tongue (2), uterus leiomyoma (2), oesophageal leiomyoma
(1), squamous cell cancer of the oesophagus (1) and stomach
adenocarcinoma (4).
Antibodies
Two Mabs were used. K-20, recognising common P-subunit
of VLA-4 (CD 29), has been well characterised as reported
previously (Amiot et al., 1986; also see the materials of the
3rd and 4th International Workshops on Human Leucocyte
Differentiation Antigens). ICO-10 Mab against human Thy-I
antigen has been produced in the Laboratory of Clinical
Radioimmunology, All-Union Cancer Research Centre of the
AMS USSR. The specificity and other characteristics of these
antibodies have been published elsewhere (Baryshnikov,
1984; Baryshnikov et al., 1985b).
Immunohistology
The expression of immunological markers was assayed in
cryostat tumour serial sections in an indirect immunofluor-
escence (IF) procedure (all the cases listed above). In some
cases (see Table I) with a positive reaction the additional
immunoenzyme staining was used. As second antibodies for
the indirect IF test, F(ab)'2-fragments were used, prepared by
the method of Janossy (1981) from FITC-labelled polyvalent
rabbit antisera against mouse immunoglobulins (Gamaleya
Institute of Epidemiology and Microbiology AMS USSR),
diluted 1:20. In immunoenzyme assays the same dilution of
peroxidase labelled antibodies against mouse globulins was
used (Gamaleya Institute, Moscow). As control, supernatants
of non-producing mouse myeloma R3-X63-Ag8.653 were
used. The IF procedure in cryostat sections was performed as
described elsewhere (Zikiryakhodzhaev et al., 1987). The re-
sults were evaluated using a Leitz microscope (FRG). The
immunoenzyme staining of tumour sections was by the stan-
dard procedure reported elsewhere (Bourne, 1983). Tumour
sections were fixed in acetone at 4'C for 10 min, with subse-
quent stages at room temperature. The sections were incu-
bated in medium 199, pH 7.2-7.4 for 10 min, and thereafter
the endogenous peroxidase of cells was inhibited using 3%
solution of hydrogen peroxide. Mabs were incubated for
30min and washed in medium 199 for 10min. Peroxidase-
labelled antisera against mouse globulins was added for
30min and washed in medium 199 for 10min. The reaction
was visualised using diaminobenzidine. Its solution was pre-
pared and filtered ex tempora (1 mg in 2 ml of Tris-buffer
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plus 4pl of 33% H202). Sections were washed in medium 199
for 10 min. Cell nuclei were stained with Mayer's haema-
toxylin.
Results
The expression of Thy-I antigen on solid tumour cells was
examined in 24 cases of varying types of neuroblastoma, two
of neurosarcoma, two of malignant neurolemmoma, 10 of
various histological types of soft tissue sarcomas, two of
teratoblastoma, two of hepatoblastoma, 13 of nephroblas-
toma, two of squamous cell cancer of the tongue, one of
colon adenocarcinoma, one squamous cell cancer of the
oesophagus, one oesophageal leiomyoma and one cervical
leiomyoma. Thy-l antigen was expressed in 79% of cases of
neuroblastoma; it was also detected in all the cases of neuro-
sarcoma, malignant neurolemmoma, teratoblastoma, leiomy-
oma and in 70% of cases of soft tissue sarcomas. The
expression of Thy-1 antigen was most marked in case of
rhabdo- and leiomyosarcoma. Membrane antigen expression
was noted on all ICO-10+ tumour cells. No expression was
found on tumours of epithelial origin: colon adenocarcin-
oma, squamous cell cancer of the tongue and oesophagus,
nephroblastoma, hepatoblastoma. In the case of nephroblas-
toma with predominance of rhabdomyosarcoma, Thy-1 anti-
gen was noted in muscle but not epithelial elements. When
tumour sections contained normal muscle tissue (oesophageal
and stomach cancer), Thy-1 antigen expression was noted on
smooth muscle cell membrane.
The expression of Thy-1 antigen was also examined in 10
cases of neuroblastoma metastases to bone marrow and in
one case to lymph nodes. It was found on blast cells of eight
out of 10 cases of neuroblastoma with bone marrow involve-
ment. The incidence rate of ICO-10+ cells was related to the
extent of lesion and varied from 5 to 25%. More than 50%
of ICO-10+ malignant cells were found in the lymph node
lesion of a patient with neuroblastoma.
Mab K20-detected common P-chain of VLA complexes
was noted on tumour cell membrane of mainly epithelial and
smooth muscle origin. The specific action was noted in
squamous cell cancer of the tongue (2 of 2 cases), and
oesophagus (1 of 1 case), nephroblastoma (4 of 4 cases),
immature teratoma (2 of 2 cases), hepatoblastoma (2 of 2
cases), oesophageal leiomyoma (1 of 1 case), cervical leio-
myoma (1 of 1 case), adrenal cortex adenoma (1 of 1 case)
and colon adenocarcinoma (1 of 1 case). VLA-p-positive cells
were also detected in nephroblastoma lung metastases (1 of 1
case). Along with tumour cells, K20 antibodies recognised
the antigen on vascular endothelial cells, blood cells, smooth
muscle cells (cytoplasmatic location of antigen), basal layer
of stratified epithelium and monolayer epithelium.
K20 Mabs did not stain in the cases of neurogen tumour:
neuroblastoma (2 cases of 2), ganglioneuroma (1 of 1 case),
malignant neurolemmoma (1 of 1 case), neurosarcoma (1 of
1 case) and neurofibrosarcoma (1 of 1 case). No VLA
antigen was found in the cases of neuroblastoma metastases
to lymph nodes (1 of 1 case) and adrenal cortex (1 of 1 case).
In the latter case K20 Mabs reacted with the remaining
epithelial cells. Neither striated muscles nor rhabdomyosar-
coma (1 of 1 case) revealed gpl20/200 glycoprotein complex.
In the case of nephroblastoma with predominance of rhab-
domyosarcoma, K20 Mabs recognised the antigen on neph-
roblastoma cells while ICO-10 Mabs reacted with rhab-
domyosarcoma elements. In the case of skin fibrosarcoma,
ICO-10 Mabs reacted with tumour cells while K20 Mabs
reacted with basal cells of stratified squamous skin epi-
thelium. No reaction with K20 Mabs was noted in the case
of soft tissue sarcomas (see Table I). In the case of K20-
tumour cells antigen-positive endothelial cells and lymphoid
elements were noted in tumour sections.
According to the reaction pattern of ICO-10 and K20
Mabs, four groups of tumours can be distinguished. Table I
summarises tumour immunophenotypes identified with the
use of ICO-10 and K20 Mabs in combination. The following
groups of solid tumours were identified:
Table I Immunoclassification of solid tumours on the basis of Thy-I and VLA-P expression
Reaction with Mab
Immunological phenotype Morphological type oftumour ICO-1O K20
ICO-10+ K20- Neuroblastoma +a
Neuroblastoma +
Ganglioneuroma +
Neuroblastoma metastases
to lymph nodes +
to adrenal cortex +
Malignant neurolemmoma +
Neurosarcoma +
Neurofibrosarcoma +
Fibrosarcoma +
Rhabdomyosarcoma +
Synovial sarcoma +
K20+ ICO-10- Nephroblastoma -+
Nephroblastoma -+
Nephroblastoma -+
Nephroblastoma -+
Nephroblastoma -+
Colon adenocarcinoma -+
Squamous cell cancer of the tongue -+
Squamous cell cancer of the tongue -+
Hepatoblastoma -+
Hepatoblastoma -+
Adrenal cortex adenoma -+
Squamous cell cancer of the oesophagus -+
ICO-10+ K20+ Immature teratoma + +
Immature teratoma + +
Cervical leiomyoma + +
Oesophageal leiomyoma + +
ICO-10- K20- Malignant fibrous histiocytoma
Malignant fibrous histiocytoma
a _ designates that Mab did notdetect antigen-positive tumourcellsin tumoursections; + designates a positive reaction ofMabwith tumourcells.
Inall casesofpositive reaction with oneofthe two orboth Mabsadditional immunoperoxidase stainingoftheremainingsectionswasused toconfirm
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1. ICO-10' and K20-: this group includes neuroblas-
tomas, malignant neurolemmomas, neurosarcomas and soft
tissue sarcomas.
2. K20+ and ICO-10-: this group includes squamous cell
cancer of the tongue and oesophagus, adrenal cortex aden-
oma, colon adenocarcinoma, hepatoblastoma and nephro-
blastoma.
3. ICO-10+ and K20+: this group includes immature tera-
toma, cervical and oesophageal leiomyoma.
4. ICO-10- and K20-: this group includes only two cases
of malignant fibrous histiocytoma.
Discussion
The VLA family includes at least five distinct heterodimers,
each composed of a unique a-subunit noncovalently assoc-
iated with a common P-subunit. In our research we used
K20, the best known antibodies recognising the common
P-subunit. One of the functions of related molecules compris-
ing the integrins superfamily is to mediate adhesion. Several
members of VLA family have been shown to bind extracel-
lular matrix proteins but the function of VLA-4 has been
obscure as yet. VLA-4 is the only VLA molecule detected on
resting T-cells. Recently (Groux et al., 1989) it has been
shown that an antibody which recognises the P-subunit of
VLA-4 (CD 29) on T-cells can inhibit CD4+ cell proliferation
triggered via CD2 or CD3. VLA-4 functions in cell-to-cell
interactions and serves the target for the suppressive effects
exerted by CD8 on CD4 cells.
We were very interested in the results reported by Amiot et
al. (1986): K20 reacted with some tumour cells in suspension
as quantified automatically by flow cytometry. To investigate
further this phenomenon we used a number of acetone-fixed
tumour sections in our experiments. This approach proved
helpful both for detection of antigen-positive cells and for
identification of the type of antigen expression: membrane,
cytoplasmic or extracellular. Morphologically antigen-posi-
tive cells in cases of antigen-negative tumours could be also
identified. The well-known Thy-l antigen was used as an
additional marker. This particular combination of mono-
clonals to the two antigens was selected for our experiments
because of the quite different patterns of reactivity of these
antibodies with malignant tumours: Thy-l mainly reacted
with neuroblastoma and some soft tissue sarcomas while K20
mainly reacted with different carcinomas. No data on simul-
taneous usage of these markers in tumour phenotyping have
been published as yet.
We have described here the distribution of two antigens
identified by two Mabs, K20 and ICO-10, in a number of
solid tumours. These antibodies belong to the group of Mabs
specifically reacting with some tumour cells and are helpful
for subvariant identification, staging and immunophenotyp-
ing of solid tumours.
K20 Mab specifically reacted with malignant cells of epi-
thelial origin as well as with tumour cells in smooth muscles.
This antibody usually identified endothelial cells, basal layer
epithelium and a small subset of lymphocytes in tumour
tissue sections. The tissue distribution of the antigen formed
a broad network surrounding all the tumour cells in tissue
sections. No reaction was noted in soft tissue sarcomas,
neuroblastoma, neurosarcoma or malignant neurolemmoma.
Our experiments showed that ICO-10 Mab-detected Thy-l
antigen was expressed on cells of neuroblastoma, neurosar-
coma, malignant neurolemmoma, teratoblastoma, rhabdo-
myosarcoma and some other soft tissue sarcomas. No anti-
gen expression was found on tumour cells ofepithelial origin.
ICO-10 Mabs are helpful for diagnosing neuroblastoma
metastases to lymph nodes, adrenal cortex and bone marrow.
Immunodiagnosis of bone marrow neuroblastoma metastases
using ICO-10 Mabs is of particular clinical interest (in nor-
mal bone marrow Thy-1 antigen expression is found only in
0.1% cells) since the difficulties arising in the course of
morphological identification of metastatic neuroblastoma
cells are well known.
Thus, the two types of antibodies used in our experiments,
K20 (VLA-4) and ICO-10 (Thy-1) seem to be helpful for
immunophenotyping of solid tumours when used in combina-
tion. These antibodies may be used as additional tools in the
studies of human solid tumours alongside specific markers
for malignant tumours, and the combination of the two
antibodies seems helpful. The functional role of the antigens
identified by these antibodies in tumour sections requires
further studies.
The authors are grateful to Mrs 0. Andrushkevish for general
management and the translation of this article.
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